China Sky One Medical, Inc. Acquires Drug to Treat Brea...( HARBIN China Oct. 28 /Xinhua-- Ch...),Health

HARBIN, China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that it recently reached an agreement to purchase a proprietary breast drug from Harbin Medical University for the treatment of lobular hyperplastic lesions of the breast.

Heilongjiang Tianlong Pharmaceutical Company, a subsidiary of China Sky One Medical, will purchase the breast drug for RMB 10 million (USD $1.46 million) from Harbin Medical University. The drug is intended to treat lobular hyperplasia in women, a type of mastitis that may lead to breast cancer. It is believed that lobular hyperplasia is brought about by stress, over work, and an irregular, high-pressure lifestyle. There are currently no drugs on the market dedicated to treating the disease, which is estimated to affect 36 million women in China.

China Sky One Medical collaborated with Harbin Medical University to develop the drug, which has been approved by the State Food and Drug Administration (SFDA) in China. First phase clinical trials have been completed. In over 10,000 trials, the drug has been shown to be 100% effective with an 89% curability rate. Following the completion of additional clinical trials, the Company expects to obtain production approval for the drug from the SFDA in two to three years following the purchase.

"We are very excited about the prospects for this drug, and estimate that it will generate RMB 1 billion (USD $146.2 million) within five years once production begins," said Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medic
'/>"/>